CORBUS PHARMACEUTICALS HOLDINGS INC.
Company Snapshot
Company Overview
Headquartered in Massachusetts, Corbus Pharmaceutical is a clinical-stage biopharmaceutical company focused on the provision of solutions for the treatment of fibrotic, inflammatory diseases and rare chronic disease. The company reported net sales as $4.82 million for the financial year of 2018.
Corbus’s lead product is Lenabasum, an oral, novel synthetic, particular (CB2) agonist intended to determine fibrotic and inflammation processes. Lenabasum is intended to treat cystic fibrosis disease, systemic sclerosis disease, dermatomyositis disease and systemic lupus erythematosus disease. The company’s main therapeutic areas include systemic sclerosis (SSc), dermatomyositis (DM), cystic fibrosis and systemic lupus erythematosus (SLE). Corbus has developed the CRB-4001 drug with the financial support from the National Institutes of Health (NIH). The purpose of CRB-4001 is to wipe-out blood-brain barrier penetration. In 2019, the company began the Phase I clinical investigation of CRB-4001.
Corbus is developing more than 600 novel compounds that focus on the endocannabinoid system. The company also focuses on the endocannabinoid system (ECS), which helps in the treatment of fibrosis and chronic inflammation in the body and regulates the brain activity and immune system.
CORBUS PHARMACEUTICALS HOLDINGS INC. In News
Company's Business Segments
- Product : CRB-701, CRB-601, CRB-913, Others
- Service : Clinical Research, Trial Management, Others
Applications/End User Industries
- Pharmaceuticals
- Healthcare
- Research Organizations
- Regulatory Bodies
- Biotechnology